Pharmacokinetic Profile of Oral Magnesium Hydroxide
Dolberg MK, Nielsen LP, Dahl R
Basic & clinical pharmacology & toxicology · 8 citas
Cómo se estudió
- Diseño
- Ensayo clínico controlado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- Institut for Klinisk Medicin, Aarhus Universitet
Según 1 financiador declarado.
Publicación
- Publicado
- 2016-07-14 · Basic Clin Pharmacol Toxicol · vol. 120 · número 3 · págs. 264–269
- Editorial
- Wiley
- Citado
- 16 citas · más que el 78% de estudios similares · 1.2× el promedio de su campo
- Referencias
- 38 trabajos
- Acceso
- De pago
- Áreas de investigación
- Magnesium in Health and Disease · Foreign Body Medical Cases · Esophageal and GI Pathology
- Palabras clave
- Magnesium, Pharmacokinetics, Hydroxide, Pharmacology, Chemistry, Medicine, Inorganic chemistry, Organic chemistry
- MeSH
- humans, magnesium hydroxide, administration, oral, infusions, intravenous, area under curve, cross-over studies, biological availability, half-life, adult, male, young adult, healthy volunteers
3 autores
- Mette Konow Bøgebjerg Dolberg🇩🇰 · autor de correspondenciaAarhus University Hospital
- Lars Peter Nielsen🇩🇰Aarhus University Hospital
- Ronald Dahl🇩🇰Aarhus University Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Despite the presumption of a beneficial effect of magnesium (Mg) supplementation on various diseases, little is known concerning the pharmacokinetics of Mg hydroxide. This study was designed to provide a pharmacokinetic profile of Mg hydroxide after a single oral dose. Ten healthy male adults participated in this cross-over study with three 24-hr study days. Interventions were (i) none (baseline), (ii) oral intake of three (3 × 360 mg) tablets of Mg hydroxide (Mablet® ) and (iii) IV bolus infusion of 2 g Mg sulphate (index drug). Blood samples were collected before the single dose, after (i.e. after treatment administration) 15, 30, 60, 90 and 120 min. and after 3, 4, 6, 8, 12 and 24 hr. Urine was collected in four 6-hr periods per study day. Blood (N = 10) and urine (N = 6) Mg were analysed by descriptive statistics. Bioavailability was 14.9% (CI: 8.3; 26.8), blood clearance was 5.1 L/hr (CI: 2.1; 17.0), apparent volume of distribution was 60.2 L (CI: 35.6; 102.0), elimination constant was 0.08 per hour (CI: 0.05; 0.14), half-life was 8.3 hr (CI: 4.8; 14.1), Cmax was 0.11 mmol/L (CI: 0.07; 0.14), and AUC[0-24] was 92.3 mmol/L × min. (CI: 45.5; 139.1). Urine Mg excretion augmented by 17.7% (CI: 8.9; 35.0) from baseline. No severe side effects were observed. The bioavailability of Mg hydroxide was 15%, and it constitutes a clinically relevant option for oral Mg supplementation. No severe side effects were seen.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.